Cardiac amyloidosis : An update on diagnosis and treatment
Cardiac amyloidosis : An update on diagnosis and treatment
复制标题
DOI：
10.3949/ccjm.84.s3.02
复制
发表时间：
2017-12-01
影响因子：
6.1
通讯作者：
Hanna, Mazen
中科院分区：
文献类型：
--
作者：
Donnelly, Joseph P.;Hanna, Mazen
心脏淀粉样变性（CA），曾经被认为是一种罕见的疾病，越来越多的认识，由于提高临床意识和更好的诊断成像。CA越来越受到心脏病学界的高度关注，因为轻链淀粉样变性（AL）的治疗策略更有效，甲状腺素运载蛋白淀粉样变性（ATTR）的治疗方法也越来越多。此外，使用单克隆抗体逆转受影响器官中的淀粉样蛋白沉积正在临床试验中积极测试。高度怀疑和系统的方法来诊断CA可以导致转诊到专业中心进行及时治疗。
Cardiac amyloidosis (CA), once thought to be a rare disease, is increasingly recognized due to enhanced clinical awareness and better diagnostic imaging. CA is becoming of heightened interest to the cardiology community given more effective treatment strategies for light chain amyloidosis (AL), as well as emerging therapies for transthyretin amyloidosis (ATTR). Furthermore, reversing amyloid deposition in affected organs using monoclonal antibodies is actively being tested in clinical trials. A high index of suspicion and a systematic approach to the diagnosis of CA can lead to referral to a center of expertise for timely treatment.